Zhang D - Search Results

1

Integrins regulate stemness in solid tumor: an emerging therapeutic target.

Xiong J, Yan L, Zou C, Wang K, Chen M, Xu B, Zhou Z, Zhang D. Xiong J, et al. Among authors: zhang d. J Hematol Oncol. 2021 Oct 29;14(1):177. doi: 10.1186/s13045-021-01192-1. J Hematol Oncol. 2021. PMID: 34715893 Free PMC article. Review.

2

Gene expression profiling of porcine skeletal muscle satellite cells after poly(I:C) stimulation.

Tran-Thi TN, Wang S, Adetula AA, Zou C, Omar AI, Han JL, Zhang DX, Zhao SH. Tran-Thi TN, et al. Gene. 2019 May 5;695:113-121. doi: 10.1016/j.gene.2018.12.059. Epub 2019 Jan 8. Gene. 2019. PMID: 30633943

3

RBM38 in cancer: role and mechanism.

Zou C, Wan Y, He L, Zheng JH, Mei Y, Shi J, Zhang M, Dong Z, Zhang D. Zou C, et al. Among authors: zhang m, zhang d. Cell Mol Life Sci. 2021 Jan;78(1):117-128. doi: 10.1007/s00018-020-03593-w. Epub 2020 Jul 8. Cell Mol Life Sci. 2021. PMID: 32642788 Review.

4

The spliceosome as a new therapeutic vulnerability in aggressive prostate cancer.

Zou C, Zhang D. Zou C, et al. Among authors: zhang d. Mol Cell Oncol. 2020 Jun 18;7(5):1778420. doi: 10.1080/23723556.2020.1778420. eCollection 2020. Mol Cell Oncol. 2020. PMID: 32944637 Free PMC article.

5

A m⁶Avalue predictive of prostate cancer stemness, tumor immune landscape and immunotherapy response.

Zou C, He Q, Feng Y, Chen M, Zhang D. Zou C, et al. Among authors: zhang d. NAR Cancer. 2022 Mar 25;4(1):zcac010. doi: 10.1093/narcan/zcac010. eCollection 2022 Mar. NAR Cancer. 2022. PMID: 35350771 Free PMC article.

6

Bone marrow-confined IL-6 signaling mediates the progression of myelodysplastic syndromes to acute myeloid leukemia.

Mei Y, Ren K, Liu Y, Ma A, Xia Z, Han X, Li E, Tariq H, Bao H, Xie X, Zou C, Zhang D, Li Z, Dong L, Verma A, Lu X, Abaza Y, Altman JK, Sukhanova M, Yang J, Ji P. Mei Y, et al. Among authors: zhang d. J Clin Invest. 2022 Sep 1;132(17):e152673. doi: 10.1172/JCI152673. J Clin Invest. 2022. PMID: 35900794 Free PMC article.

7

YY1 complex in M2 macrophage promotes prostate cancer progression by upregulating IL-6.

Chen S, Lu K, Hou Y, You Z, Shu C, Wei X, Wu T, Shi N, Zhang G, Wu J, Chen S, Zhang L, Li W, Zhang D, Ju S, Chen M, Xu B. Chen S, et al. Among authors: zhang l, zhang g, zhang d. J Immunother Cancer. 2023 Apr;11(4):e006020. doi: 10.1136/jitc-2022-006020. J Immunother Cancer. 2023. PMID: 37094986 Free PMC article.

8

An integrated ceRNA network identifies miR-375 as an upregulated miRNA playing a tumor suppressive role in aggressive prostate cancer.

Chen M, Zou C, Tian Y, Li W, Li Y, Zhang D. Chen M, et al. Among authors: zhang d. Oncogene. 2024 Apr 2. doi: 10.1038/s41388-024-03011-6. Online ahead of print. Oncogene. 2024. PMID: 38565944

9

Identification of an anaplastic subtype of prostate cancer amenable to therapies targeting SP1 or translation elongation.

Zou C, Li W, Zhang Y, Feng N, Chen S, Yan L, He Q, Wang K, Li W, Li Y, Wang Y, Xu B, Zhang D. Zou C, et al. Among authors: zhang d, zhang y. Sci Adv. 2024 Apr 5;10(14):eadm7098. doi: 10.1126/sciadv.adm7098. Epub 2024 Apr 3. Sci Adv. 2024. PMID: 38569039 Free PMC article.

10

Intron retention is a hallmark and spliceosome represents a therapeutic vulnerability in aggressive prostate cancer.

Zhang D, Hu Q, Liu X, Ji Y, Chao HP, Liu Y, Tracz A, Kirk J, Buonamici S, Zhu P, Wang J, Liu S, Tang DG. Zhang D, et al. Nat Commun. 2020 Apr 29;11(1):2089. doi: 10.1038/s41467-020-15815-7. Nat Commun. 2020. PMID: 32350277 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

42,161 results

Search Page